Compare SIMO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | IBRX |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2005 | N/A |
| Metric | SIMO | IBRX |
|---|---|---|
| Price | $113.56 | $6.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $105.00 | $11.80 |
| AVG Volume (30 Days) | 715.1K | ★ 46.1M |
| Earning Date | 02-03-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 8.75 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $798,326,000.00 | $82,555,000.00 |
| Revenue This Year | $10.15 | $680.06 |
| Revenue Next Year | $16.36 | $90.18 |
| P/E Ratio | $39.35 | ★ N/A |
| Revenue Growth | N/A | ★ 1025.95 |
| 52 Week Low | $37.21 | $1.83 |
| 52 Week High | $127.67 | $8.28 |
| Indicator | SIMO | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.78 | 75.41 |
| Support Level | $111.00 | $5.71 |
| Resistance Level | $127.67 | $8.28 |
| Average True Range (ATR) | 9.29 | 0.67 |
| MACD | 0.00 | 0.42 |
| Stochastic Oscillator | 57.43 | 67.10 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid state storage devices. Its only operating segment is to develop NAND flash controllers and SSDs solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.